시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 골암 치료 시장 보고서(2025년)
Bone Cancer Treatment Global Market Report 2025
상품코드 : 1824345
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

골암 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 5.9%를 나타내 17억 2,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 헬스케어 정책의 변화, 환자 중심의 케어 모델로의 시프트, 원격의료와 원격 모니터링의 확대, 암 환자 증가, 효과적인 치료법의 이용 불능, 부작용 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 골암 계발을 위한 정부의 대처, 헬스케어 기기의 기술진보, 연구개발활동 증가, 유전자편집기술의 탐구와 개발, 학계, 제약회사, 헬스케어기관의 협력관계 강화 등을 들 수 있습니다.

향후 5년간의 성장률 5.9%라고 하는 예측은 전회의 예측으로부터 0.1%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 스위스와 프랑스에서 개발된 사지 구제용 의지와 방사성 의약품의 가격을 상승시켜 육종 치료 지연과 정형외과 종양 치료비의 상승을 초래하여 미국 종양 치료를 저해할 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

골암의 유병률 증가는 골암 치료 시장 확대를 촉진할 것으로 예측됩니다. 뼈암은 뼈 조직에서 발생하는 악성 종양의 한 그룹으로 구성되어 뼈에서 통제 불가능한 세포 분열과 증식에 기인합니다. 골암 치료 전략은 수술 개입, 사지 온존, 통증 완화, QOL 향상, 효과적인 종양 관리 등 환자에게 몇 가지 장점을 제공하는 것을 목표로 합니다. 2023년 2월 미국 임상종양학회(ASCO)의 보고에 따르면 미국에서는 3,970명의 원발성 골육종이 새롭게 진단되었으며, 그 내역은 남성이 2,160명, 여성이 1,810명으로, 15세-19세 환자에서 2013년 400명으로부터 증가를 반영했습니다. 이와 같이, 골암의 유병률 증가는 골암 치료 시장 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

The term 'bone cancer treatment' encompasses the methodologies employed to address and combat bone cancer, a form of cancer originating in bone tissue. This treatment is applied to both primary bone cancers, originating within the bone, and secondary bone cancers, which initiate in another part of the body and subsequently spread to the bone.

The principal categories of bone cancer treatment include multiple myeloma, osteosarcoma, chondrosarcoma, and Ewing sarcoma. Multiple myeloma is a cancer affecting plasma cells, a subtype of white blood cells responsible for antibody production. Treatment modalities for multiple myeloma encompass various approaches such as chemotherapy, targeted therapy, radiation therapy, surgery, and others. The distribution channels for these treatments include hospital pharmacies, drug stores and retail pharmacies, as well as online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The bone cancer treatment market research report is one of a series of new reports from The Business Research Company that provides bone cancer treatment market statistics, including bone cancer treatment industry global market size, regional shares, competitors with a bone cancer treatment market share, detailed bone cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bone cancer treatment industry. This bone cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bone cancer treatment market size has grown strongly in recent years. It will grow from $1.3 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to evolution of imaging technologies, refinement of biopsy techniques, discovery and advancement in pharmaceuticals, improvements in healthcare infrastructure, advancements in supportive care.

The bone cancer treatment market size is expected to see strong growth in the next few years. It will grow to $1.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to changes in healthcare policies, shift towards patient-centric care models, expansion of telemedicine and remote monitoring, increasing number of cancer patients, unavailability of effective treatment and side effects. Major trends in the forecast period include government initiatives for bone cancer awareness, technological advancements in healthcare devices, increasing research and development activities, exploration and development of gene-editing techniques, increased collaboration between academia, pharmaceutical companies, and healthcare institutions.

The forecast of 5.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology care by inflating prices of limb-salvage prosthetics and radiopharmaceuticals developed in Switzerland and France, resulting in delayed sarcoma treatments and higher orthopedic oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of bone cancer is anticipated to fuel the expansion of the bone cancer treatment market. Bone cancer comprises a group of malignant tumors that originate in bone tissue, resulting from uncontrolled cell division and growth in the bone. Treatment strategies for bone cancer aim to provide several advantages to patients, encompassing surgical interventions, limb preservation, pain relief, improved quality of life, and effective tumor management. As per reports from the American Society of Clinical Oncology (ASCO) in February 2023, an estimated 3,970 new cases of primary bone sarcoma are expected to be diagnosed in the US, with 2,160 in men and 1,810 in women, reflecting an increase from 400 cases in 2013 among individuals aged 15 to 19. Thus, the increasing prevalence of bone cancer acts as a driving force for the bone cancer treatment market.

The growth of the bone cancer treatment market is further expected to be propelled by the rise in the geriatric population. The term 'geriatric population' refers to individuals aged 65 years and older. Bone cancer treatment is essential for this demographic as the disease often originates in the bone cells of long bones, and its incidence tends to increase with age. Advanced treatment options are available to address the specific needs of older adults and enhance treatment outcomes. According to the World Health Organization, globally, by 2030, 1 in 6 people will be 60 or older, and this age group is projected to double to 2.1 billion by 2050. In the UK, the House of Commons Library reported in June 2021 that by 2043, the senior population is expected to constitute 24% of the total population, reaching 17.4 million people. Hence, the rise in the geriatric population serves as a driving factor for the growth of the bone cancer treatment market.

Major companies in the bone cancer treatment market are concentrating on the introduction of immunotherapy to deliver targeted therapies that leverage the body's immune system to more effectively combat cancer. Immunotherapy is a type of cancer treatment that utilizes the immune system to attack cancer cells. For example, in July 2023, MedPacto, a drug developer based in South Korea, received orphan drug designation from the European Medicines Agency (EMA) for its drug vactosertib, intended for the treatment of osteosarcoma. Vactosertib specifically targets and inhibits the TGF-beta (transforming growth factor-beta) signaling pathway, which is associated with tumor progression and metastasis. The orphan drug designation for vactosertib marks a significant advancement in the development of new therapies for osteosarcoma, providing hope for enhanced treatment options for patients suffering from this rare and aggressive form of bone cancer.

Major players in the bone cancer treatment market are actively introducing next-generation drugs, including prescription medicines, to gain a competitive advantage. Prescription medicines are pharmaceutical drugs that can only be legally obtained with a written order from a qualified healthcare professional, such as a doctor or dentist. For instance, in September 2023, GSK plc, a UK-based pharmaceutical and biotechnology company, launched Ojjaara (Momelotinib), a prescription medicine designed to treat certain types of myelofibrosis (MF) in adults. Myelofibrosis is a rare form of bone marrow cancer that disrupts the normal production of blood cells. Ojjaara (Momelotinib) offers a novel and effective treatment option for patients grappling with bone cancer and anemia.

In July 2022, GSK plc, a pharmaceutical company based in the UK, acquired Sierra Oncology for $1.9 billion. This acquisition strengthens GSK's ability to treat bone cancer, particularly with the addition of momelotinib, a drug specifically designed for patients with myelofibrosis. Sierra Oncology Inc. is a biotechnology company located in the US that specializes in targeted therapies for bone cancer treatment.

Major companies operating in the bone cancer treatment market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Incyte Corporation, Ipsen SA, Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Exelixis Inc., BeiGene Ltd., Daiichi Sankyo Company Limited, Karyopharm Therapeutics.

North America was the largest region in the bone cancer treatment market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the bone cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bone cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The bone cancer treatment market includes revenues earned by entities by providing diagnosis and staging, supportive care, multidisciplinary care, biopsy, pain management, and psychosocial support services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bone Cancer Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bone cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bone cancer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bone cancer treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Bone Cancer Treatment Market Characteristics

3. Bone Cancer Treatment Market Trends And Strategies

4. Bone Cancer Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bone Cancer Treatment Growth Analysis And Strategic Analysis Framework

6. Bone Cancer Treatment Market Segmentation

7. Bone Cancer Treatment Market Regional And Country Analysis

8. Asia-Pacific Bone Cancer Treatment Market

9. China Bone Cancer Treatment Market

10. India Bone Cancer Treatment Market

11. Japan Bone Cancer Treatment Market

12. Australia Bone Cancer Treatment Market

13. Indonesia Bone Cancer Treatment Market

14. South Korea Bone Cancer Treatment Market

15. Western Europe Bone Cancer Treatment Market

16. UK Bone Cancer Treatment Market

17. Germany Bone Cancer Treatment Market

18. France Bone Cancer Treatment Market

19. Italy Bone Cancer Treatment Market

20. Spain Bone Cancer Treatment Market

21. Eastern Europe Bone Cancer Treatment Market

22. Russia Bone Cancer Treatment Market

23. North America Bone Cancer Treatment Market

24. USA Bone Cancer Treatment Market

25. Canada Bone Cancer Treatment Market

26. South America Bone Cancer Treatment Market

27. Brazil Bone Cancer Treatment Market

28. Middle East Bone Cancer Treatment Market

29. Africa Bone Cancer Treatment Market

30. Bone Cancer Treatment Market Competitive Landscape And Company Profiles

31. Bone Cancer Treatment Market Other Major And Innovative Companies

32. Global Bone Cancer Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bone Cancer Treatment Market

34. Recent Developments In The Bone Cancer Treatment Market

35. Bone Cancer Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기